v3.25.4
Investments in Group Enterprises and Associates (Tables)
12 Months Ended
Dec. 31, 2025
Investments accounted for using equity method [abstract]  
Summary of Investments in Group Enterprises and Associates

Ascendis Pharma A/S’s (parent company) investments in group enterprises and associates at December 31, 2025 comprise:

Subsidiaries

 

Domicile

 

Ownership

 

Ascendis Pharma GmbH

 

Germany

 

 

100

%

Ascendis Pharma Endocrinology GmbH

 

Germany

 

 

100

%

Ascendis Pharma, LLC

 

USA

 

 

100

%

Ascendis Pharma Endocrinology, Inc.

 

USA

 

 

100

%

Ascendis Pharma, Ophthalmology Division A/S

 

Denmark

 

 

100

%

Ascendis Pharma Endocrinology Division A/S

 

Denmark

 

 

100

%

Ascendis Pharma Bone Diseases A/S

 

Denmark

 

 

100

%

Ascendis Pharma Growth Disorders A/S

 

Denmark

 

 

100

%

Ascendis Pharma Oncology Division A/S

 

Denmark

 

 

100

%

Ascendis Pharma Europe A/S

 

Denmark

 

 

100

%

Ascendis Pharma UK Limited

 

United Kingdom

 

 

100

%

Ascendis Pharma Iberia S.L.

 

Spain

 

 

100

%

Ascendis Pharma France SASU

 

France

 

 

100

%

Ascendis Pharma Italia S.R.L.

 

Italy

 

 

100

%

Ascendis Pharma Sverige AB

 

Sweden

 

 

100

%

Ascendis Pharma Switzerland GmbH

 

Switzerland

 

 

100

%

Ascendis Pharma Belgium BV

 

Belgium

 

 

100

%

ASND Portugal, Unipessoal, Lda.

 

Portugal

 

 

100

%

 

 

 

 

 

Associates

 

Domicile

 

Ownership

 

VISEN Pharmaceuticals

 

Cayman Island

 

 

39.2

%

Eyconis Inc.

 

USA

 

 

33.2

%